CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash flows used in operating activities:
Net loss	$ (66,649)	$ (27,467)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	251	262
Amortization of intangibles and interest accretion of contingent consideration	66,241	14,057
Amortization of deferred financing costs	1,961	1,391
Interest accretion of notes receivable	(127)	(243)
Deferred income tax benefit	(10,159)	(5,344)
Loss on disposal of equipment	19	160
Stock compensation expense	4,428	3,397
Fair market value change in derivative liability	(19,230)	0
Fair market value change in contingent consideration	(3,596)	0
Accretion of debt discount	1,436	0
Issuance of stock for inducement	19,500	0
Expense for stock options issued in exchange for services	0	119
Loss on sale of PML (including impairment)	0	6,659
Cancellation of ParaPRO stock options in connection with termination of contract	0	(1,294)
(Increase) decrease in operating assets
Accounts receivable	(16,461)	(26,197)
Income taxes	(6,194)	(4,085)
Inventory	(182)	1,650
Prepaid expenses and other assets	3,002	(2,547)
Increase (decrease) in operating liabilities
Accounts payable and accrued expenses	15,019	16,229
Accrued allowances	5,354	0
Interest payable	(2,957)	0
Other liabilities	(2,551)	0
Net cash used in operating activities	(10,895)	(23,253)
Cash flows from investing activities:
Acquisition of TREXIMET®	(2,836)	(253,000)
Payments received on notes receivable	4,850	4,850
Proceeds from sale of PML	0	1,137
Acquisition of Zohydro ER®	(83,341)	0
Proceeds from sale of certain Cypress intangible assets	0	135
Proceeds from sale of property and equipment	0	43
Purchase of equipment	(1,029)	(561)
Net cash used in investing activities	(82,356)	(247,396)
Cash flows from financing activities:
Net proceeds from issuance of Convertible Notes	130,000	65,000
(Payments) proceeds from Treximet Secured Notes	(10,013)	220,000
Net drawdowns on credit facilities	2,655	1,923
Payments for financing costs	(5,045)	(14,064)
Payment of consent fee	(2,150)	0
Payments on mortgages and capital leases	(28)	(46)
Payments on contracts payable	0	(2,500)
Proceeds from issuance of common stock, net of tax	285	2,018
Stock issuance costs	(9)	0
Tax benefit on stock-based awards	0	(147)
Shares withheld for the payment of taxes	(112)	(753)
Net cash provided by financing activities	115,583	271,431
Net increase in cash and cash equivalents	22,332	782
Cash and cash equivalents, beginning of period	34,855	15,647
Cash and cash equivalents, end of period	$ 57,187	$ 16,429